VCEL: Vericel Corporation Company Short-Term Debt

This chart of Vericel Corporation (VCEL) quotes on the GURU.Markets platform demonstrates the dynamics of a company developing unique tissue regeneration and burn treatment methods. However, geopolitical instability complicates the logistics of fragile medications and reduces profits due to exits from several foreign markets. Meanwhile, experienced management is effectively scaling sales, and the indicator stands at 0.02, confirming management transparency and the growing demand for products.

Vericel Corporation is developing high-margin MACI cell technologies, which is reflected in the dynamics of the company's short-term liabilities. This indicator captures the volume of borrowings with a maturity of up to one year. The metric measures the current debt load, which is sensitive to operating expenses related to expansion into arthroscopic surgery. A downward trend indicates effective liquidity management; however, capital concentration in a single asset remains risky.